"Designing Growth Strategies is in our DNA"

Uterine Fibroid Drugs Market Size, Share & Industry Analysis, By Drug Class (GnRH Antagonists, GnRH Agonists, and Others), By Type (Intramural Fibroid, Submucosal Fibroid, and Others), By Route of Administration (Oral and Parenteral), By Application (Shrinkage, Pain Management, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Forecasts, 2026-2034

Last Updated: January 26, 2026 | Format: PDF | Report ID: FBI114341

 


ATTRIBUTE

DETAILS

Study Period

2021-2034

Base Year

2025

Estimated Year

2026

Forecast Period

2026-2034

Historical Period

2021-2024

Growth Rate

CAGR of 14.03% from 2026-2034

Unit

Value (USD Billion)

Segmentation

By Drug Class, Type, Route of Administration, Application,  Distribution Channel, and Region

By   Drug Class

·         GnRH Antagonists

·         GnRH Agonists

·         Others

By Type

·         Intramural Fibroid

·         Submucosal Fibroid

·         Others

By Route of Administration

·         Oral

·         Parenteral

By Application

·         Shrinkage

·         Pain Management

·         Others

By Distribution Channel

·         Hospital Pharmacies

·         Retail Pharmacies & Drug Stores

·         Online Pharmacies

By Geography

·         North America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country)

o   U.S.

o   Canada

·         Europe (By Drug Class, Type, Route of Administration, Application, Distribution Channel, Distribution Channel, and Country/Sub-region)

o   Germany

o   U.K.

o   France

o   Spain

o   Italy

o   Scandinavia

o   Rest of Europe

·         Asia Pacific (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)

o   China

o   Japan

o   India

o   Australia

o   Southeast Asia

o   Rest of Asia Pacific

·         Latin America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)

o   Brazil

o   Mexico

o   Rest of Latin America

·         Middle East & Africa (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)

o   GCC

o   South Africa

o   Rest of the Middle East & Africa

  • 2021-2034
  • 2025
  • 2021-2024
  • 167
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann